来凯医药-B:LAE102、LAE103及LAE123临床和临床前研究结果在2025年ADA大会上公布

格隆汇
Jun 23

格隆汇6月23日丨来凯医药-B(02105.HK)宣布:(i)用于治疗肥胖症的LAE102(一种针对Act RI IA的单克隆抗体)的I期单剂量递增(SAD)研究结果;以及(ii)LAE102、LAE103(一种针对ActRIIB的单克隆抗体)及LAE123(一种针对Act RIIA/IIB双靶点的单克隆抗体)作为增肌减脂疗法的临床前研究结果,已于美国糖尿病协会(ADA)第85届科学年会上公布。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10